Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model

Radium-223 dichloride and enzalutamide are indicated for metastatic castration-resistant prostate cancer and their combination is currently being investigated in a large phase 3 clinical trial. Here, we evaluated the antitumor efficacy of radium-223, enzalutamide, and their combination in the intrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Suominen, Mari I., Knuuttila, Matias, Schatz, Christoph A., Schlicker, Andreas, Vääräniemi, Jukka, Sjöholm, Birgitta, Alhoniemi, Esa, Haendler, Bernard, Mumberg, Dominik, Käkönen, Sanna-Maria, Scholz, Arne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916479/
https://www.ncbi.nlm.nih.gov/pubmed/36768509
http://dx.doi.org/10.3390/ijms24032189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916479/
https://www.ncbi.nlm.nih.gov/pubmed/36768509
http://dx.doi.org/10.3390/ijms24032189

Ejemplares similares